Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Another secondary endpoint was the percent change in body weight from baseline to Week 72
iu kin bo qun Nhit khng qu 30 C
The most commonly reported adverse effects in Phase 2 trials were gastrointestinal in nature, including: Nausea (the most frequently reported) Vomiting Diarrhoea Constipation Decreased appetite These effects were generally dose-dependent and most pronounced during dose escalation, typically improving over time
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
The most important rule is simple: do not increase, reduce, skip, or stop your medication without speaking with the healthcare professional managing your treatment
US$ 27.06
US$ 22.21
US$ 21.46
US$ 20.85
US$ 29.61
US$ 20.54
US$ 27.27
